A Single Institution, Prospective, Non-randomized Study of Partial Breast Irradiation Using the MammoSite Radiation Therapy System (Breast Brachytherapy Applicator)
- To examine the efficacy of MammoSite® Radiation Therapy System (RTS) in delivering
partial-breast irradiation to women with early-stage breast cancer.
- To assess the toxicities associated with MammoSite® RTS in these patients.
- To evaluate the cosmetic results in the breast after brachytherapy with the MammoSite®
- To correlate the cosmetic results with the use of chemotherapy, volume of the implant,
and distance from the implant to the skin.
- To correlate the local recurrence rate with time between surgery and implant.
OUTLINE: Patients undergo placement of the MammoSite® Radiation Therapy System (RTS) device
into the cavity where the tumor was removed either at the time of surgery or percutaneously
under ultrasound guidance after surgery. Within 2-5 days after the device implant, patients
undergo partial-breast irradiation delivered by MammoSite® RTS twice daily for 5 days.
After completion of study therapy, patients are followed up periodically for 5 years.
Allocation: Non-Randomized, Primary Purpose: Treatment
Proportion of local recurrence at 5 years
Edward Kim, MD
Ohio State University Comprehensive Cancer Center